News

While BDSI plans to pursue an indication for the maintenance treatment of opioid dependence, the company has also secured the rights and plans to develop a product for

EPP is characterized by an extreme risk of severe burns of the skin resulting in intolerable pain, swelling, scarring and a state of distress. The company said that

The latest acquisition will be combined with CSL’s existing vaccines and pharmaceutical subsidiary, bioCSL. The transaction requires regulatory approvals and is expected to be completed in the second

Targin is a fixed combination of opioid agonist oxycodone and opioid antagonist naloxone in prolonged-release oral tablets. The drug, which is currently licensed for the treatment of RLS

The drug secured CHMP positive opinion for treatment of mCRPC patients who are asymptomatic or mildly symptomatic after failure of androgen-deprivation therapy in whom chemotherapy is not yet

AHA is a very rare and potentially life-threatening acute bleeding disorder that typically affects older adults and occurs in both males and females. Obizur, which contains a recombinant

Lundbeck is currently addressing requests specified in the letter, and is committed to making Carbella available in 2015, pending FDA approval. "We are working closely with the FDA

The company also announced Dropless media coverage from AAO meeting, where it introduced a new white paper, titled, "Making Dropless Cataract Surgery Possible". Imprimis currently provides two proprietary

After positive negotiations with major international affiliate marketers, Alternaturals is confident that the company will see significant growth in 2015 to warrant its own facility. As a result,